TRIAL DETAIL

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma

Drug:
Trial Name:
A Study of R1507 in Patients With Recurrent or Refractory Sarcoma
NCT#:
Conditions:
Sarcoma
Status:
Does not allow GIST
Phase:
2
Start Date 07/01/2008
Age of Trial (yrs) 13.4
Treatment Phase:
Gleevec-resistant
Drug Category:
IGF1R inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
SARC011 NO21157
Sponsor:
Hoffman-La Roche, SARC
Patient Contact:
Contact: Please reference Study ID Number: NO21157 973-235-5000 Contact: Please reference Study ID Number: SARC011 734-930 7600 (FOR US ONLY)
Contact email:
Contact Phone:
734-930 7600
Randomized:
IV or Oral:
Intravenous
Trial Notes:
NOTE: Per SARC, this trial does not allow GIST patients.

This trial specifies several sarcomas but not specifically GIST. As of 5/18/09 all previously opened sites are active but not recruiting except for Paris France.
Trials of IGF1R inhibitors such as R1507, would be most appropriate for patients with wild-type GIST and/or pediatric GIST.

Trial Links

 
 
 

Trial Results

Drug Information

Genmab description of R1507
 
10/23/2007 - Roche Announces Positive Results in IGF-1R (R1507) Study and Plans for Future SARC Studies
 
Roche halts development of R1507
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
100 Blossom St
Charlestown
MA
02114
USA
Omaha
NB
68114
USA
3181 S.W. Sam Jackson Park Rd.
Portland
OR
97239
USA
2000 Circle of Hope
Salt Lake City
UT
84103
USA
10 St Andrews Place
East Melbourne
Victoria
3002
Australia
Villejuif
Val de Narne
94805
France
Lille
Nord
59020
France
Munster
68167
Germany
Mannheim
68135
Germany
Lund
SE-221 85
Sweden
550 Wilmslow Rd
Manchester
Lancashire
M20 4BX
UK
Paris
75248
France